Abstract:MGluR2 is G protein-coupled receptor that is targeted for diseases like anxiety, depression, Parkinson’s disease and schizophrenia. Herein, we report the three-dimensional quantitative structure–activity relationship (3D-QSAR) studies of a series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists. Two series of models using two different activities of the antagonists against rat mGluR2, which has been shown to be very similar to the human mGluR2, (activity I: inhibition of [3H]-LY354740; activity II: mGluR2 (1S,3R)-ACPD inhibition of forskolin stimulated cAMP.) were derived from datasets composed of 137 and 69 molecules respectively. For activity I study, the best predictive model obtained from CoMFA analysis yielded a Q2 of 0.513, R2ncv of 0.868, R2pred = 0.876, while the CoMSIA model yielded a Q2 of 0.450, R2ncv = 0.899, R2pred = 0.735. For activity II study, CoMFA model yielded statistics of Q2 = 0.5, R2ncv = 0.715, R2pred = 0.723. These results prove the high predictability of the models. Furthermore, a combined analysis between the CoMFA, CoMSIA contour maps shows that: (1) Bulky substituents in R7, R3 and position A benefit activity I of the antagonists, but decrease it when projected in R8 and position B; (2) Hydrophilic groups at position A and B increase both antagonistic activity I and II; (3) Electrostatic field plays an essential rule in the variance of activity II. In search for more potent mGluR2 antagonists, two pharmacophore models were developed separately for the two activities. The first model reveals six pharmacophoric features, namely an aromatic center, two hydrophobic centers, an H-donor atom, an H-acceptor atom and an H-donor site. The second model shares all features of the first one and has an additional acceptor site, a positive N and an aromatic center. These models can be used as guidance for the development of new mGluR2 antagonists of high activity and selectivity. This work is the first report on 3D-QSAR modeling of these mGluR2 antagonists. All the conclusions may lead to a better understanding of the mechanism of antagonism and be helpful in the design of new potent mGluR2 antagonists.

Study of 3D-QSAR of 5-HT 6 receptor antagonists

Investigation of the Structure Requirement for 5-HT6 Binding Affinity of Arylsulfonyl Derivatives: A Computational Study

Structure-based 3D-QSAR Studies on Thiazoles As 5-HT3 Receptor Antagonists

Studies of H4R Antagonists Using 3D-QSAR, Molecular Docking and Molecular Dynamics

Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.

3-DQSAR Study on the Analogues of 3-phenyl-1-indan-amines as SSRIs by the Comparative Molecular Field Analysis(CoMFA)

Combinatorial QSAR Modeling of Specificity and Subtype Selectivity of Ligands Binding to Serotonin Receptors 5HT1E and 5HT1F.

3D-QSAR Studies on AChE Inhibitory Activities of 2-Phenoxy-indan-1-one Derivatives

Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT 2A Receptor by In Silico Methods.

Three-dimensional quantitative structure–activity relationship study for analogues of TQXs using CoMFA and CoMSIA

Studies of Phenylethynyl-pyrrolo[1,2-a]pyrazine as mGluR5 Antagonists Using 3D-QSAR Method

3D-QSAR analyses of melatonin antagonists

Three-Dimensional Quantitative Structure-Activity Relationship Analyses of A Series of Butenolide Eta Antagonists

Studies of New Fused Benzazepine As Selective Dopamine D3 Receptor Antagonists Using 3D-QSAR, Molecular Docking and Molecular Dynamics

Investigation on Quantitative Structure Activity Relationships and Pharmacophore Modeling of a Series of Mglur2 Antagonists

3D-QSAR Study on Phenoxyalkylamine Compounds of Α1-Adrenoceptor Antagonist

Quantitative Structure-Activity Relationship of 2-Alkyl-4-(biphenylylmethoxy) Pyridine Derivatives with AT1 Receptor Antagonistic Activity

Studies on Three-Dimensional Qsar of Muscarinic Receptor Agonists

Three-dimensional Quantitative Structural-Activity Relationship and Molecular Dynamics Study of Multivariate Substituted 4-Oxyquinazoline HDAC6 Inhibitors

Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods

Molecular field analysis of two sets of non-peptide corticotropin-releasing hormone antagonists